Oncology: Multiple Myeloma
UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus
A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With Cyclophosphamide, in Patients With Recurrent of Refractory Multiple Myeloma
University of Arkansas for Medical Science is recruiting participants to trial a drug for relapsed multiple myeloma (MM). The investigational drug utilizes the measles vaccine, a weakened virus which may restore a missing gene to MM tumor cells to make them more susceptible to the immune system and chemotherapy. This missing gene is known to be a problem in many cancers, and previous studies have shown the measles virus to help improve MM.
Participants will be given 1 dose of the investigatory drug via IV, along with a course of chemotherapy, then will be followed for a year.
- Be 18 to 75 years of age
- Meet cancer screening requirements specific to the study and MM
- ≥2 months must have elapsed after the last peripheral blood stem cell transplant prior to enrollment
- Not be HIV-positive
THE STUDY INVOLVES:
- Screening before the treatment.
- A single injection of the vaccine therapy drug will be administered along with a 4-day course of chemotherapy.
- Monitoring of the patient during treatment, then follow up for 1 year.
LOCATIONS AND CONTACTS:
The study location is at the University of Arkansas for Medical Science. Map.
Contact: Brittany Lehman | (501) 686-8274 | [email protected]
University of Arkansas
Or go online: https://clinicaltrials.gov/ct2/show/NCT02192775